×
About 3,798 results

ALLMedicine™ Giant Cell Arteritis Center

Research & Reviews  1,246 results

A Study to Evaluate the Safety and Efficacy of Upadacitinib in Participants With Giant Cell Arteritis
https://clinicaltrials.gov/ct2/show/NCT03725202

Aug 12th, 2022 - This study consists of two periods. The objective of Period 1 is to evaluate the efficacy of upadacitinib in combination with a 26-week corticosteroid (CS) taper regimen compared to placebo in combination with a 52-week CS taper regimen, as measur...

A Study to Evaluate Guselkumab for the Treatment of Participants With New-onset or Relapsing Giant Cell Arteritis
https://clinicaltrials.gov/ct2/show/NCT04633447

Aug 12th, 2022 - Giant cell arteritis (GCA) is a non-necrotizing granulomatous systemic vasculitis of unknown etiology affecting medium-sized and large arteries usually accompanied or preceded by systemic inflammation. Guselkumab is a monoclonal antibody (mAb) tha...

Studies of the Natural History, Pathogenesis, and Outcome of Idiopathic Systemic Vasculitis
https://clinicaltrials.gov/ct2/show/NCT02257866

Aug 12th, 2022 - The purpose of this protocol is to study the natural history of idiopathic systemic vasculitis in children and adults. The idiopathic vasculitides are a group of rare, systemic diseases involving inflammation of arteries and other tissue with resu...

Gadolinium-enhanced MR improved motion sensitized driven equilibrium (iMSDE) for intrac...
https://doi.org/10.1016/j.jstrokecerebrovasdis.2022.106697
Journal of Stroke and Cerebrovascular Diseases : the Offi... Tomoyose R, Miyata T et. al.

Aug 9th, 2022 - Giant cell arteritis (GCA) generally affects extracranial large and medium-sized vessels. It rarely causes intracranial vessel stenosis, presenting as cerebral infarction (CI). Consequently, accurate diagnosis of CI induced by GCA is often challen...

Teaching Video NeuroImage: Bilateral Hemifacial Spasm in Giant Cell Arteritis.
https://doi.org/10.1212/WNL.0000000000200837
Neurology Sechi E, Gallus E et. al.

Aug 9th, 2022 - Teaching Video NeuroImage: Bilateral Hemifacial Spasm in Giant Cell Arteritis.|2022|Sechi E,Gallus E,Solla P,Puggioni D,Amadu AM,|

see more →

Guidelines  7 results

2021 American College of Rheumatology/Vasculitis Foundation Guideline for the Managemen...
https://doi.org/10.1002/acr.24632
Arthritis Care & Research; Maz M, Chung SA et. al.

Jul 9th, 2021 - To provide evidence-based recommendations and expert guidance for the management of giant cell arteritis (GCA) and Takayasu arteritis (TAK) as exemplars of large vessel vasculitis. Clinical questions regarding diagnostic testing, treatment, and ma...

2021 American College of Rheumatology/Vasculitis Foundation Guideline for the Managemen...
https://doi.org/10.1002/art.41774
Arthritis & Rheumatology (Hoboken, N.J.); Maz M, Chung SA et. al.

Jul 9th, 2021 - To provide evidence-based recommendations and expert guidance for the management of giant cell arteritis (GCA) and Takayasu arteritis (TAK) as exemplars of large vessel vasculitis. Clinical questions regarding diagnostic testing, treatment, and ma...

British Society for Rheumatology guideline on diagnosis and treatment of giant cell art...
https://doi.org/10.1093/rheumatology/kez672
Rheumatology (Oxford, England); Mackie SL, Dejaco C et. al.

Jan 24th, 2020 - British Society for Rheumatology guideline on diagnosis and treatment of giant cell arteritis.|2020|Mackie SL,Dejaco C,Appenzeller S,Camellino D,Duftner C,|diagnosis,therapy,standards,

British Society for Rheumatology guideline on diagnosis and treatment of giant cell art...
https://doi.org/10.1093/rheumatology/kez664
Rheumatology (Oxford, England); Mackie SL, Dejaco C et. al.

Jan 24th, 2020 - British Society for Rheumatology guideline on diagnosis and treatment of giant cell arteritis: executive summary.|2020|Mackie SL,Dejaco C,Appenzeller S,Camellino D,Duftner C,|diagnosis,diagnostic imaging,drug therapy,therapeutic use,

2018 Update of the EULAR recommendations for the management of large vessel vasculitis.
https://doi.org/10.1136/annrheumdis-2019-215672
Annals of the Rheumatic Diseases; Hellmich B, Agueda A et. al.

Jul 5th, 2019 - Since the publication of the European League Against Rheumatism (EULAR) recommendations for the management of large vessel vasculitis (LVV) in 2009, several relevant randomised clinical trials and cohort analyses have been published, which have th...

see more →

Drugs  1 results see all →

Clinicaltrials.gov  81 results

A Study to Evaluate the Safety and Efficacy of Upadacitinib in Participants With Giant Cell Arteritis
https://clinicaltrials.gov/ct2/show/NCT03725202

Aug 12th, 2022 - This study consists of two periods. The objective of Period 1 is to evaluate the efficacy of upadacitinib in combination with a 26-week corticosteroid (CS) taper regimen compared to placebo in combination with a 52-week CS taper regimen, as measur...

A Study to Evaluate Guselkumab for the Treatment of Participants With New-onset or Relapsing Giant Cell Arteritis
https://clinicaltrials.gov/ct2/show/NCT04633447

Aug 12th, 2022 - Giant cell arteritis (GCA) is a non-necrotizing granulomatous systemic vasculitis of unknown etiology affecting medium-sized and large arteries usually accompanied or preceded by systemic inflammation. Guselkumab is a monoclonal antibody (mAb) tha...

Studies of the Natural History, Pathogenesis, and Outcome of Idiopathic Systemic Vasculitis
https://clinicaltrials.gov/ct2/show/NCT02257866

Aug 12th, 2022 - The purpose of this protocol is to study the natural history of idiopathic systemic vasculitis in children and adults. The idiopathic vasculitides are a group of rare, systemic diseases involving inflammation of arteries and other tissue with resu...

A Phase II Study of Allogeneic Hematopoietic Stem Cell Transplant for Subjects With VEXAS (Vacuoles, E1 Enzyme, X-linked, Autoinflammatory, Somatic) Syndrome
https://clinicaltrials.gov/ct2/show/NCT05027945

Aug 5th, 2022 - Background: In 2019, investigators at the National Institutes of Health defined a new disease syndrome named VEXAS: Vacuoles in bone marrow cells, E1 enzyme mutations, X-linked, Autoinflammatory, Somatic syndrome. This syndrome is characterized by...

Predictive Factors for Treatment Response in Patients With Newly-diagnosed Polymyalgia Rheumatica and Giant Cell Arteritis
https://clinicaltrials.gov/ct2/show/NCT05479448

Aug 5th, 2022 - Polymyalgia rheumatica (PMR) and giant cell arteritis (GCA) are closely related inflammatory rheumatic diseases. The first-line treatment of both PMR and GCA are glucocorticoids (GC). In PMR, initial oral prednisone equivalent doses in between 10 ...

see more →

News  179 results

Giant Cell Arteritis Fast-Track Clinics Pave Way for Greater Ultrasound Use in US
https://www.medscape.com/viewarticle/964298

Dec 7th, 2021 - Temporal artery biopsy has been the standard for diagnosing giant cell arteritis (GCA), but vascular ultrasound, a procedure that's less invasive, less time-intensive, less expensive, and more convenient, has gained widespread use in Europe, and n...

Secukinumab beat placebo for sustained remission of giant cell arteritis after steroid taper
https://www.mdedge.com/rheumatology/article/249001/lupus-connective-tissue-diseases/secukinumab-beat-placebo-sustained
Tara Haelle

Nov 22nd, 2021 - Patients with giant cell arteritis (GCA) remained in remission longer when they took secukinumab (Cosentyx) during a 6-month–long taper of glucocorticoids, a monoclonal antibody drug that inhibits interleukin-17A, compared with placebo, according.

Secukinumab Sustained Remission of GCA After Steroid Taper
https://www.medscape.com/viewarticle/963473

Nov 22nd, 2021 - Patients with giant cell arteritis (GCA) remained in remission longer when they took secukinumab (Cosentyx) during a 6-month–long taper of glucocorticoids, a monoclonal antibody drug that inhibits interleukin-17A, compared with placebo, according ...

Tocilizumab Shortage Continues as Pandemic Wears On
https://www.medscape.com/viewarticle/956882

Aug 19th, 2021 - With worldwide supplies of tocilizumab dwindling as the COVID-19 pandemic rages on, a shortage of the agent will persist "for at least the next several weeks," according to Genentech, the Roche unit that manufactures tocilizumab under the trade na...

Tocilizumab After Ultra-Short Course Steroids Promising for Newly Diagnosed Giant Cell Arteritis
https://www.medscape.com/viewarticle/954712

Jul 16th, 2021 - NEW YORK (Reuters Health) - Tocilizumab (TCZ) induced a slow and lasting remission after an ultra-short pulse (three days) of steroids in newly diagnosed giant cell arteritis (GCA) patients, a proof-of-concept trial shows. His early research on cy...

see more →

Patient Education  5 results see all →